Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

被引：2
|
作者：
Pipe, Steven [1 ]
Collins, Peter [2 ]
Dhalluin, Christophe [3 ]
Kenet, Gili [4 ,5 ]
Schmitt, Christophe [3 ]
Buri, Muriel [3 ]
Jimenez-Yuste, Victor [6 ]
Peyvandi, Flora [7 ,8 ]
Young, Guy [9 ]
Oldenburg, Johannes [10 ]
Mancuso, Maria Elisa [11 ,12 ]
Kavakli, Kaan [13 ]
Kiialainen, Anna [3 ]
Chang, Tiffany [14 ]
Lehle, Michaela [3 ]
Niggli, Markus [3 ]
Fijnvandraat, Karin [15 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Cardiff Univ, Sch Med, Cardiff, Wales
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Tel Aviv Univ, Tel Aviv, Israel
[6] Univ Autonoma Madrid, La Paz Univ Hosp Idi Paz, Madrid, Spain
[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[8] Univ Milan, Milan, Italy
[9] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[10] Univ Bonn, Bonn, Germany
[11] IRCCS Humanitas Res Hosp, Rozzano, Italy
[12] Humanitas Univ, Rozzano, Italy
[13] Ege Univ, Fac Med, Childrens Hosp, Izmir, Turkiye
[14] Spark Therapeut Inc, San Francisco, CA USA
[15] Univ Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177963
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [22] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [23] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Fredrik Jonsson
    Christophe Schmitt
    Claire Petry
    Francois Mercier
    Nicolas Frey
    Sylvie Retout
    Clinical Pharmacokinetics, 2021, 60 : 931 - 941
  • [24] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    BLOOD, 2022, 140 : 13041 - 13042
  • [25] Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Jonsson, Fredrik
    Schmitt, Christophe
    Petry, Claire
    Mercier, Francois
    Frey, Nicolas
    Retout, Sylvie
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 931 - 941
  • [26] Factor VIII use in the treatment of breakthrough bleeds in persons with haemophilia a without inhibitors on emicizumab prophylaxis: the phase III HAVEN 3 study experience
    Callaghan, M.
    Trzaskoma, B.
    Ko, R.
    Lee, L.
    Patel, A.
    Tzeng, E.
    Shah, M.
    Chang, T.
    Niggli, M.
    Dhalluin, C.
    Paz-Priel, I.
    Mahlangu, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 44 - 45
  • [27] Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
    Reyes, Adriana
    Revir, Cedric
    Niggli, Markus
    Chebon, Sammy
    Schlagmueller, Simone
    Flacke, Jan-Paul
    Zortel, Max
    Paz-Priel, Ido
    Asikanius, Elina
    Hampton, Roger
    Mahajan, Anadi
    Schmidt, Elvira
    Edwards, Susan C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2079 - 2087
  • [28] Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
    Shima, Midori
    Suzuki, Nobuaki
    Nishikii, Hidekazu
    Amano, Kagehiro
    Ogawa, Yoshiyuki
    Kobayashi, Ryota
    Ozaki, Ryoto
    Yoneyama, Koichiro
    Mizuno, Narumi
    Sakaida, Emiko
    Saito, Makoto
    Okamura, Takashi
    Ito, Toshihiro
    Hattori, Norimichi
    Higasa, Satoshi
    Seki, Yoshinobu
    Nogami, Keiji
    THROMBOSIS AND HAEMOSTASIS, 2024,
  • [29] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
    Mahlangu, Johnny
    Jimenez-Yuste, Victor
    Ventriglia, Giuliana
    Niggli, Markus
    Barlera, Simona
    Hermans, Cedric
    Lehle, Michaela
    Chowdary, Pratima
    Jew, Lyle
    Windyga, Jerzy
    Frenzel, Laurent
    Schmitt, Christophe
    Castaman, Giancarlo
    Pipe, Steven W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)
  • [30] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
    Callaghan, Michael U.
    Negrier, Claude
    Paz-Priel, Ido
    Chang, Tiffany
    Chebon, Sammy
    Lehle, Michaela
    Mahlangu, Johnny
    Young, Guy
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Niggli, Markus
    Howard, Monet
    Bienz, Nives Selak
    Shima, Midori
    Jimenez-Yuste, Victor
    Schmitt, Christophe
    Asikanius, Elina
    Levy, Gallia G.
    Pipe, Steven W.
    Oldenburg, Johannes
    BLOOD, 2021, 137 (16) : 2231 - 2242
12345